CRMD Earnings

CRMD reported its earnings on 2026-05-14, showcasing a revenue of 127.43M against an estimate of 109.85M, resulting in a 16% surprise. The EPS was 0.43, surpassing the expected 0.34 by 22.86%. The stock experienced a 5.73% price change on the earnings day and a 4.27% change over the next five days, reflecting market reactions to the results.

Following CRMD's earnings announcement on 2026-05-14, the stock price moved by 5.73% on the day of the release. Over the subsequent five days, it saw a 4.27% change. Historically, CRMD's stock price tends to shift by an average of 3.02% in the 10 days leading up to earnings and 7.37% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate CRMD's annual revenue to reach 127.57M, while the EPS is projected at 0.72. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CRMD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CRMD's stock price typically moves by 3.02% in the 10 days before its earnings and 7.37% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.72 and revenue of 127.57M.

The earnings call reveals strong financial performance with increased net income and adjusted EBITDA. The company reaffirmed its guidance and highlighted market opportunities for its products. Despite some uncertainties in trials and regulatory feedback, management's optimistic guidance and strategic focus on Medicare Advantage expansion are positive indicators. The Q&A section did not reveal significant negative concerns, maintaining a positive sentiment. However, lack of specific details on trial amendments and pricing strategies limits stronger optimism. Overall, the positive financial results and strategic initiatives suggest a likely stock price increase in the short term.